Mylan collaborates with CSIR for management of COVID-19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ clinical-trials-well-proven-drugs-partnership-industry-towards-development-multiple-therapeutic-options-covid19
A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration

The Council of Scientific & Industrial Research (CSIR), India’s premier research organization, and Mylan Laboratories Limited, the India-based subsidiary of leading global pharmaceutical company Mylan, today announced a partnership to address unmet patient needs amidst the evolving COVID-19 pandemic. Under the partnership, CSIR’s constituent laboratory Indian Institute of Chemical Technology (CSIR-IICT), and Mylan will collaborate to identify potential therapies for COVID-19.

A series of clinical trials will be conducted towards new and innovative solutions to manage COVID-19 pandemic in India as part of this collaboration. The first of the clinical trial to be rolled out is a multiple arm phase 3 study that will be conducted in adult patients with mild to moderate COVID -19 at risk of complications.

Director-General of CSIR, Dr Shehkar C Mande stated, “The current collaboration with Mylan is a significant milestone and during the current COVID-19 pandemic, CSIR has prioritized conducting clinical trials of well-proven drugs in partnership with industry towards the development of multiple therapeutic options for COVID-19.”

Director of CSIR-IICT, Dr Chandrasekhar said, “CSIR is delighted to associate with Mylan as knowledge and scientific partner, and looks forward to working with the company, especially given Mylan’s vast industry experience in clinical trials and commercialization.”

Mylan Chief Operating Officer, Sanjeev Sethi stated, “Our collaboration with CSIR is a strategic step forward aimed at identifying effective treatments for patients with COVID-19. In addition to bringing forward new indications, this partnership will also help us identify multiple molecules that can potentially be leveraged in therapies for various other infectious diseases in the future.”

The application for the clinical trials has been submitted to the Drugs Controller General of India (DCGI) for regulatory approval.

CSIR has appointed Dr Ram Vishwakarma, Honorary Advisor to DG-CSIR and former Director CSIR-IIIM (Indian Institute of Integrative Medicine) as a mentor to lead this collaboration.

The Council of Scientific & Industrial Research (CSIR), known for its cutting-edge R&D knowledgebase in diverse Science & Technology areas, is a contemporary and premier R&D organization. Having a pan-India presence, CSIR has a dynamic network of 38 national laboratories, 39 outreach centres, 3 Innovation Complexes and 5 units. CSIR covers a wide spectrum of science and technology – from oceanography, geophysics, chemicals, drugs, genomics, biotechnology and nanotechnology to mining, aeronautics, instrumentation, environmental engineering and information technology.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. It is one of the world's largest producers of active pharmaceutical ingredients.

Tags : #Mylan #CSIR #DCGI #SanjeevSethi #LatestPharmaCollaboration #DrRamVishwakarma

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

Why Modern Lifestyle Causes Chronic InflammationAugust 05, 2026
Endometriosis Awareness: Understanding the Silent Condition Affecting Millions of Indian WomenAugust 05, 2026
A Complete Guide to Pregnancy Health Tips for Indian Women: Nutrition, Wellness, and What Every Expectant Mother Should KnowAugust 05, 2026
Why Preventive Healthcare for Children Is One of the Most Important Investments India Can MakeAugust 04, 2026
The Role of Pathology in Healthcare: From Diagnosis to Disease PreventionAugust 04, 2026
Pathophysiology of Psoriatic Arthritis: Clinical Presentation, Joint Damage Mitigation, and BiologicsAugust 04, 2026
Comprehensive Evaluation of Syncope: Cardiac vs. Neurological Origin WorkupsAugust 04, 2026
Common Medical Terms Explained: A Plain-Language Guide for Indian Patients and Healthcare SeekersAugust 03, 2026
Why Radiology Is the Backbone of Modern Medical Diagnosis and TreatmentAugust 03, 2026
Managing Urban Stress: Science-Backed Strategies for Mental Resilience in 2026 August 01, 2026
Managing Chronic Inflammation: The Role of Anti-Inflammatory Indian SuperfoodsAugust 01, 2026
Pathophysiology of Psoriatic Arthritis: Clinical Presentation, Joint Damage Mitigation, and BiologicsAugust 01, 2026
Early Markers of Glaucoma: Structural vs. Functional Ophthalmic Diagnostic ProtocolsAugust 01, 2026
Managing Complex Diabetic Foot Ulcers: Multidisciplinary Wound Care, Offloading, and RevascularizationAugust 01, 2026
The Future of Preventive Medicine: How India Is Moving From Cure to PreventionAugust 01, 2026
Why Young Indians Are Facing Heart Problems: Causes, Symptoms, and PreventionAugust 01, 2026
The Future of Preventive Screening: AI-Driven Early Cancer Detection in IndiaJuly 31, 2026
The Impact of Climate Change on Allergic Respiratory Diseases in Indian Cities July 31, 2026
Electronic Medical Records: What They Are, Why They Matter, and How India Is Embracing ThemJuly 31, 2026
Heatwave Health Risks in India: Symptoms, Treatment, and Prevention StrategiesJuly 31, 2026